A previous study [20] reported that patients with gliomas bearing IDH mutations show better response to chemo-radiation therapy and thus present favorable clinical outcome corroborating the need for 2HG detection to guide clinical management [20–23]. The gene discussed is IDH1; the disease is glioma.